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Abstract
Exosomes are nano-sized vesicles that are formed during inward budding of multivesic-
ular bodies and the maturation of endosomes. They are secreted by almost all cell types 
under normal, pathological, and physiological conditions. They are found in mostly all 
biological fluids, such as breast milk, blood, urine, and semen. Exosomes are involved 
in cell-to-cell communication through the biological transfer of lipids, proteins, DNAs, 
RNAs, mRNAs, and miRNAs. Exosomes are enriched in tetraspanins, enzymes, heat 
shock proteins, and membrane trafficking proteins. There are numerous techniques that 
are used to isolate, purify, and characterize exosomes from biofluids. Isolation/purifica-
tion techniques include ultracentrifugation, filtration, sucrose density gradient centrifu-
gation, etc. Characterization techniques include flow cytometry, electron microscopy, 
NanoSight tracking analysis, Western blot, etc. These techniques are often used to help 
principal investigators understand the properties and biological functions of exosomes. 
However, some of these techniques can be very complicated and challenging, resulting 
in various drawbacks. Exosomes can be used as potential carriers for therapeutics. Thus, 
they can serve as biomarkers to diagnosis various diseases that are associated with can-
cer, genetics, viruses, bacteria, parasites, etc. Therefore, with advances in science and 
technology, many innovative techniques have been established to exploit the biological 
properties of exosomes.
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1. The discovery of exosomes
In the early 1980s, researchers Pan, Stahl, and Johnstone discovered a complex mode of extra-
cellular vesicle (EV) secretion while studying the loss of transferrin during the maturation of 
reticulocytes in blood [1–4]. EVs were believed to bud directly from plasma membrane frag-
ments that were isolated from cultured cells and human bodily fluids [1, 2, 5–7]. The research 
group showed that small vesicles were formed by inward budding inside an intracellular 
endosome which lead to the formation of multivesicular bodies (MVBs) [1, 8–10]. The MVBs 
produce intraluminal vesicles (ILVs) and fuse with the plasma membrane, releasing their con-
tents into the extracellular environment [1, 8, 9]. The ILVs were termed “exosomes” in the late 
1980s by Johnstone [2, 9]. Since their discovery approximately 40 years ago [3, 4, 8], exosomes 
have gained tremendous attention due to their involvement in intercellular communication 
[11]. EVs were originally believed to be waste products of the cell [8, 12, 13]. We currently 
recognize EVs as much more.
2. Exosome biogenesis and secretion
Exosomes are generated in the endosomal membrane when the ILVs of MVBs are formed 
during the maturation of early and late endosomes [1]. During maturation, MVBs are fated 
for lysosomal degradation or fused with the plasma membrane which leads to the secretion of 
ILVs as exosomes [1, 14]. The generation of the ILVs in MVBs contains the lateral segregation 
of cargo at the endosomal limiting membrane [15, 16]. In addition, it involves the formation of 
an inward budding vesicle and the release in the endosomal lumen of the membrane vesicle 
containing a small portion of cytosol [15, 16].
The Endosomal Sorting Complex Responsible for Transport (ESCRT) mediates exosome 
biogenesis [1, 17–19]. ESCRTs consist of approximately 20 proteins that are divided into the 
ESCRT-0, -I, -II, and –III complexes [20, 21]. These complexes contain ubiquitin-binding sub-
units [18, 21, 22]. The ESCRT-0 complex identifies and sequentially binds to ubiquitylated 
proteins in the endosomal membrane [23]. The ESCRT-I and -II complexes are responsible for 
membrane deformation into buds with sequential cargo [21]. The ESCRT-III complex drives 
vesicle scission [21, 24].
ESCRT-0 contains the hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) 
protein [22]. HRS identifies ubiquitylated cargo proteins and other constituents in a complex 
that consist of clathrin, the epidermal growth factor receptor pathway substrate 15 gene, and 
signal-transducing adaptor molecule [18, 25]. Most importantly, HRS recruit tumor suscep-
tibility gene 101 of the ESCRT-I complex [26]. ESCRT-I is then involved in the recruitment of 
ESCRT-III, through ESCRT-II or the ESCRT-accessory protein ALG-2 interacting protein-X 
(Alix) [26]. Lastly, the separation and recycling of the ESCRT machinery interacts with the 
AAA-ATPase vacuolar protein sorting 4 [19, 27].
Exosomes are secreted by many cell types during normal, physiological, and pathological 
conditions [14, 28, 29]. They are secreted from cancer cells [28, 30], platelets [31], neurons 
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[32], epithelial cells [28, 33, 34], dendritic cells [28, 35], B and T cells [28, 36], astrocytes [28, 
37], endothelial cells [28, 38], mast cells [31, 39], and mesenchymal stem cells [28, 40]. Also, 
exosomes have been identified in most bodily fluids, such as nasal secretion [28, 41], blood 
[42], serum [28, 43], ascites [44], amniotic fluid [44], urine [28, 45], breast milk [28, 46], and 
saliva [28, 43].
Depending on the cell type, exosomes are mainly secreted by the constitutive release pathway 
and/or inducible release pathway [28, 47–51]. In the constitutive secretion pathway, proteins 
are sorted into vesicles in the Golgi and transported to the cell surface where they fuse with 
the plasma membrane via exocytosis. In addition, Rab guanosine triphosphatases (GTPases) 
[52, 53], hetrotrimeric G-protein [52], protein kinase D [52, 54], glycosphingolipids, and flotil-
lin [52] are involved in this pathway. Specifically, several Rab GTPases have been shown 
to act as key regulators of the exosome secretory pathway [49]. Rabs are a large group of 
small GTPases that regulate protein transport via endocytic and exocytic pathways in all cell 
types [52, 55]. In addition, Rabs are involved in membrane trafficking (i.e. vesicle budding, 
membrane fusion, and the transport of vesicles along actin and tubulin) [53]. Rab GTPases 
are composed of approximately 70 distinct proteins [56, 57]. Common Rab proteins include 
Rab11, Rab27, and Rab35 [58, 59]. These proteins are all involved in the transport of endoly-
sosomal vesicles toward the plasma membrane [60].
Rab11 was the first Rab GTPase reported study that involved exosome secretion in human 
leukemic K562 cells by Savina et al. [61, 62]. Specifically, Rab11 is involved in the recycling 
from an endosomal compartment to the plasma membrane [63–65]. Both Rab27a and Rab 
27b function in MVE docking at the plasma membrane in several cancer cell lines in vivo and 
in vitro [49, 55, 66]. Rab35 mediates MVB docking or tethering in oligodendroglia cells as 
reported by Hsu et al.[58, 61]. They revealed that the inhibition of Rab35 leads to intracellular 
accumulation of endosomal vesicles and impairs exosome secretion [58, 61]. In addition, Hsu 
et al. showed that Rab35 localizes to the surface of oligodendroglia in a GTP-dependent man-
ner, where it regulates vesicular density [58, 61].
Inducible secretion is regulated by many cellular processes [67–69]. This pathway is regulated 
by stimuli, such as heat shock, hypoxia [52], DNA damage [52, 67, 70], increased intracellular 
calcium release [52, 67, 70], thrombin [52], extracellular ATP [52, 67], and lipopolysaccharide 
39 stimulation [35, 52]. In 2012, King et al. demonstrated that the release of exosomes in 
breast cancer cells is promoted by hypoxia [71]. In addition, they demonstrated the hypoxic 
response could potentially be mediated by the hypoxia-inducible factor-1α—a group of 
transcription factors that are targeted for degradation under normal oxygen conditions by 
the action of specific O
2
−, iron- and 2-oxoglutarate dependent prolyl hydroxylases [71, 72]. 
Another study was reported by Hooper and colleagues in 2012 [73]. In their study, they 
investigated the inducible release of exosomes cultured from rat microglia cells treated with 
recombinant carrier-free Wnt3a protein- a family of cysteine rich glycoproteins that play a 
role in tumorigenesis and act as morphogens during development [69, 73]. They observed 
that these Wnt3-induced cells increased exosome secretion through a glycogen synthase 
kinase 3-independent mechanism [73]. The process of exosome biogenesis and secretion is 
summarized in Figure 1.
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3. Composition of exosomes
Exosomes carry a group of specific proteins, lipids, RNA, microRNA (miRNA), and DNAs, 
that represents their cells of origin [28, 56, 74], as depicted in Figure 2. Recent studies have 
shown that exosomes contain approximately 194 lipids, 4563 proteins, 1639 messenger RNAs 
(mRNAs), and 764 miRNAs [28, 75–77]. Exosomes are enriched in molecules, such as the major 
histocompatibility molecules (MHC) class I and II that play a key role in immunoregulation 
by processing antigenic peptides [28, 78]. Also, exosomes contain tetraspanins that serve as 
unique markers [79]. Tetraspanins include: cluster of differentiation (CD) 9, CD63, CD81, and 
CD82, as well as adhesion molecules CD54 and CD11b [26, 28, 78]. In addition, exosomes are 
enriched with heat shock proteins (hsps) which act as chaperones and play a key role in cel-
lular responses that are associated with environmental stress. Hsps assist with protein folding 
and trafficking. Common exosomal proteins include Hsp60, Hsp70, Hsp90, and heat shock 
protein cognate 70 [16, 78]. Along with tetraspanins and hsps, exosomes contain cytoplasmic 
proteins such as Rabs and annexins [26, 61]. These proteins promote the fusion of MVB with 
the cell membrane and the removal of exosomes. Clathrin, Alix, Tumor susceptibility gene 
101 (TSG) 101), and ubiquitin are exosomal constituents that are involved in the biogenesis 
of MVBs [78]. Enzymes that makeup the composition of exosomes consist of protein kinase 
G (PKG), ATPase, Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and enolase. 
Signal transduction proteins, ADP-ribosylation factor (ARF) 1, cell division control protein 
42 (CDC42), epidermal growth factor receptor (EGFR), β-catenin, guanine nucleotide-binding 
G proteins (G proteins), phosphatidylinositol 3-kinase (P13K), mucin 1 (MUC 1), 14-3-3, and 
syntenin [68, 78, 80]. Viral proteins, such as group-specific antigen (Gag), Human immuno-
deficiency virus negative regulatory factor (HIV Nef), Herpes simplex virus glycoprotein B 
Figure 1. Biogenesis and secretion of exosomes. Exosome biogenesis and secretion is a complex process. Exosome 
secretion can occur by two different mechanisms, constitutive or inducible secretion. One or both of these pathways 
maybe operational depending on the condition of the cell. Constitutive exosome secretion occurs in various cell types 
under normal physiological and pathological conditions. Inducible exosome secretion is regulated by stressors (e.g. 
pathogens, alcohol, drugs). Multivesicular bodies (MBVs), intraluminal vesicles (ILVs), Trans-Golgi network and the 
Endosomal Sorting Complex Responsible for Transport (ESCRT) are four important compartments involved in exosome 
biogenesis and secretion. Rab guanosine triphosphatases (GTPases) (7, 11, 27, 35 etc.) are also depicted, they play an 
important role in exosome secretion.
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(HSV gB), Epstein–Barr virus (EBV) gp350 also make up the composition of some exosomes 
[78, 81]. Exosomes that contain RNA can serve as an alternate pathway of cellular communi-
cation [82, 83]. Thus, mRNAs that are found in exosomes can be transferred to target cells and 
translated into proteins [84]. miRNAs, such as miR-1, miR-15, miR-16, miR-151, miR-375, and 
lethal-7 play a role in hematopoiesis, exocytosis, tumorigenesis, and angiogenesis [28, 85, 86].
4. Exosome isolation/purification methods
Exosomes are isolated from a wide spectrum of biological fluids [87, 88]. To examine the 
quality of isolated exosomes, numerous methods have been developed to examine and mea-
sure their morphology, composition, quantity, and size distribution [88, 89]. With advances 
in science and technology, many innovative techniques have been established to exploit a 
specific trait of exosomes, such as their size, shape, density, and surface proteins to aid in their 
isolation and purification [88, 90]. However, each method has advantages and disadvantages 
as shown in Table 1.
4.1. Ultracentrifugation and filtration-based exosome isolation
Ultracentrifugation is a centrifugation process used for generating acceleration up to 
100,000 × g (approx. 9800 km/s2) [88]. Differential ultracentrifugation is often used to iso-
late exosomes [88, 91]. The isolation of exosomes by differential ultracentrifugation contains 
numerous centrifugation steps, which uses centrifugal force to get rid of residual cells, cellular 
Figure 2. Composition of exosomes. Proteomic, Biochemical, and Immunological investigations have identified many 
specific proteins and RNAs present in some exosomes. This is a limited representation of common molecules present 
within some exosomes. Molecules illustrated here are grouped based on category function or protein class: Tetraspanins, 
Cytoskeletal proteins, Membrane trafficking proteins, Immunoregulator molecules, Adhesion molecules, Lipid rafts, 
Signal transduction molecules, viral proteins and RNAs.
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debris, and large vesicles [79, 88]. In addition, these steps are used to precipitate exosomes 
[79, 88]. There are various protocols available for this isolation technique. First, cell culture 
is subjected to a low speed centrifugation using a Sorvall RT600 centrifuge with a swinging 
bucket rotor (Thermo Fisher Scientific). This is applied to remove cells and apoptotic debris 
[92, 93]. Next, a higher speed is used to administer and eliminate larger vesicles, whereas, 
Isolation/purification 
methods
Mechanism Advantages Disadvantages
Differential 
ultracentrifugation [79, 91]
Remove residual 
cells, large vesicles, 
and cellular debris; 
precipitate exosomes 
[79]
Standard method used 
to isolate exosomes from 
cultured media and 
biological fluids [79, 91]
Effectiveness of the method is 
lower when biological fluids 
are used for analysis [79] 
co-precipitation of protein 
aggregates, apoptotic bodies, 
or nucleosomal fragments, 
which may lead to less sample 
purity and less correctly bound 
proteins [91]
Sucrose gradient 
centrifugation [91]
Separate vesicles based 
on their different 
flotation densities [91, 
97]
Allows separation of the 
low-density exosomes 
from other vesicles, 
particles and contaminants 
[91]
Cannot separate exosomes 
from viruses because of their 
similarities in density and size 
[91]
Filtration [79, 91] Used to separate 
exosomes from proteins 
and other macroparticles 
using ultrafiltration 
membranes [79]
Allows separation of 
soluble molecules and 
small particles from 
exosomes [79]
Loss of analysis due to 
adhesion. Contamination of 
isolated EVs. Exosomes can 
potentially be deformed or 
damaged due to additional force 
being applied pass the analyzed 
liquid through the membrane 
[79, 91]
Size exclusion 
chromatography [79]
Applies a column 
packed with porous 
polymeric beads which 
separates the particles 
based on their size [79]
Allows precise 
separation of large and 
small molecules and 
application of various 
solutions. Compared 
to centrifugation 
methods, the structure 
of exosomes isolated by 
chromatography is not 
affected by shearing force 
[79]
Requires a long running time, 
which limits applications of 
chromatographical isolation for 
processing multiple biological 
samples [79]
Microfluidics [91] Microscale isolation 
based on a variety of 
properties of exosomes 
like immunoaffinity, 
size, and density [91]
Energy efficient, portable, 
fast processing time, low 
cost, easy automation and 
integration [91]
Lack of standardization and 
large scale tests on clinical 
samples, lack of method 
validation, moderate to low 
sample capacity [91]
ExoQuick™ [91, 111] Precipitates exosomes 
overnight through 
incubation [91, 111]
Fast and easy processing; 
additional equipment is 
not needed for isolation 
[91, 111]
Lack specificity toward 
exosomes; biological fluids are 
difficult to resuspend [91, 111]
Table 1. Advantages and disadvantages of isolation/purification methods.
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the remaining media is re-suspended in phosphate buffered saline. Lastly, a high speed of 
centrifugation using a SW41T1 swinging rotor in a Beckman Coulter (Brea, CA, USA) (Optima 
L-70 K ultracentrifuge) is performed to precipitate exosomes; and the exosome pellet is stored 
at −80°C until further use [92].
Filtration is a size-based technique that is often used in combination with ultracentrifugation, 
as depicted in Figure 3, for the isolation of exosomes in in vitro studies [92–94]. Depending on 
the size of vesicles, filtration is applied to separate exosomes from proteins and other particles 
[79]. Filtration membranes that have pore sizes of 0.22, 0.45, or 0.8 μm can be used to collect 
EVs that are larger than 150 nm [79]. Although filtration is a quick isolation method, it faces 
challenges, such as contamination of isolated EVs, trapping of EVs in nano or micro pores, 
and co-purifying abundant proteins EVs isolation [91]. Because of these disadvantages, the 
maximal recovery of EVs for isolation must be optimized [91].
4.2. Sucrose density gradient centrifugation
Sucrose density gradient centrifugation is a form of centrifugation that is used to measure the 
density of exosomes in a sucrose gradient [95]. Exosomes have floatation densities ranging 
from 1.08 to 1.22 g/ml on continuous sucrose gradients [91, 96, 97]. Vesicles that are purified 
from the Golgi float at 1.05 to 1.12 g/ml; and vesicles that are purified from the endoplasmic 
reticulum float at 1.18 to 1.25 g/ml [95]. Sucrose density gradient is formed by overlapping 
lower concentrations of sucrose on higher concentrations in a centrifuge tube. For instance, a 
sucrose gradient may contain layers ranging from 70% sucrose to 20% sucrose in 10% incre-
ments [91, 96, 97]. Since exosomes are generally spread among 3 to 5 segments of the sucrose 
gradient, it is recommended to perform this separation approximately 5 times the amount of 
exosomal proteins that is needed to detect exosomes.
4.3. Size exclusion chromatography
Size exclusion chromatography (SEC) is used to separate macroparticles based on size, not 
molecular weight [79]. Currently, SEC is used to isolate exosomes that are present in urine 
[98] and blood [79, 99]. This method utilizes a column packed with porous polymeric beads 
Figure 3. Schematic illustration of differential ultracentrifugation. Cell culture media is collected and centrifuged by 
means of low speed centrifugation followed by collection of media and filtration using a 0.22-micron filter. The media 
then undergoes ultracentrifugation pelleting the exosomes which are resuspended in buffer for further use.
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Figure 4. Standard ExoQuick™ protocol. Exosomes are collected be means of several centrifugation and precipitation 
steps.
that contains several pores and tunnels. In SEC, particles pass through the beads depending 
on their diameter. Particles that contain small hydrodynamic radii can pass through the pores, 
hence resulting in late elution [88]. However, particles that contain large hydrodynamic radii, 
are excluded from entering the pores [88, 100].Correspondingly, SEC is used in combination 
with ultracentrifugation to isolate/purify exosomes [88, 101]. Rood et al. 2010 demonstrated 
that ultracentrifugation followed by SEC, significantly enriched urinary exosomes compared 
to exosomes that were obtained by ultrafiltration or ultracentrifugation alone [101, 102].
4.4. Microfluidics
Microfluidics is the study and manipulation of fluids at the microscale level by means of 
frictional forces [91, 103]. Microfluidic devices bind specific EVs to antibody-coated surfaces 
[104, 105]. The EV sample is loaded on a pump that slowly pushes the fluid through the chip. 
Microfluidic-based technologies ensure that fluid pressure is converted to high shear forces 
more consistent and efficient than other technologies. By maintaining constant pressure, micro-
fluidic homogenizers ensure that the samples receive the same treatment. As fluids are forced 
at controlled temperatures and constant pressures through the interaction chamber, particles 
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experience extremely high shear forces. As a result of these forces, particle size is reduced and 
particle size distribution curves are constricted. Advantages of this technique include a reduc-
tion in processing times, energy consumption, volumes of sample, and material costs [106, 107].
4.5. ExoQuick™
Commercial kits utilizing polyethylene glycol for isolation of exosomes are frequently used 
in research studies [108–110]. ExoQuick™ (System Biosciences, Mountain View, CA, USA) 
is the most commonly used kit [108]. This kit is quick and easy to perform, and additional 
equipment is not necessary for isolation. ExoQuick is a proprietary polymer that can be used 
to isolate exosomes for a variety of applications, including functional studies (i.e. cell-to-cell 
signaling), exosomal proteomics, biomarker studies, biology studies (i.e. tumorigenesis), 
exosomal miRNA profiling, and exosomal metabolomics/lipidomics [111–113]. With the 
ExoQuick, a mix is added to the samples and the EVs precipitate via incubation overnight. 
Recent studies have revealed that the highest yield of exosomes was obtained using a combi-
nation of ExoQuick with ultracentrifugation [91, 114, 115]. However, contamination of exo-
somal isolates with non-exosomal materials remains a concern for polymer-based isolation 
procedures. Furthermore, the polymer substance that is present in the isolate may affect the 
down-stream analysis [79]. A detailed protocol utilizing ExoQuick is depicted in Figure 4.
5. Exosome characterization methods
There are several common techniques that are used to determine the quantity, morphology, 
and size of exosomes following purification. Exosomes can be characterized using the follow-
ing techniques: flow cytometry [116], electron microscopy (EM) [117], NanoSight tracking 
analysis (NTA) [92, 117, 118], Raman spectroscopy (RS) [119], Western blot (WB) [42, 92, 120], 
and/or ExoCarta database [117, 121].
Flow cytometry is one of the most commonly used techniques used to detect the origin, size, 
and morphology of circulating EVs [116, 121]. It is a high-throughput, multi-parametric tech-
nique that quickly analyzes and quantitates thousands of single cells or particles [121, 122]. 
In this method, a laser beam with a specific wavelength is directed through a stream of a 
sheath fluid that contains suspended particles [117]. Next, the emitted scatter and fluores-
cence is captured and measured by detectors [121]. Due to their small diameter (≤200 nm), 
detecting, capturing, and examining exosomes is difficult to characterize via flow cytometry 
[123]. However, proteins that are located on the surface of exosomes can be stained with 
fluorochrome-conjugated antibodies [124].
EM is often used to characterize and visualize exosomes due their small size [117, 120]. EM 
uses a beam of electrons to generate an image of the EVs’ sample [117]. Electron beams are 
passed through the sample [117]. The electrons are collected and magnified using special 
lenses [117]. Typical morphological characteristics of exosomes are spherical shaped and 
range approximately 30–100 nm [120]. When used in conjunction with immuno-labeling, the 
surface proteins of exosomes can be determined via electron microscopy [125].
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NTA measures the concentration and size distribution of exosomes [92, 117, 126, 127]. An 
NTA device is composed of a laser light scattering microscope connected to a sensitive charge-
coupled device camera, a complementary metal–oxide–semiconductor camera, a hydraulic 
pump, a measuring chamber, and an analytical software [117, 121]. The hydraulic pump 
injects particles into the measuring chamber at a fixed flow rate and exposes them to a narrow 
laser beam [117]. Next, the movement of the illuminated particles is recorded by the com-
plementary metal-oxide-semiconductor [117]. The NTA software then identifies and tracks 
individual ECVs moving under Brownian motion and relates the movement to a particle size 
based on the Stokes-Einstein equation [128]:
  (x, y) 2  = 2  k B  T / 3  r h  πη (1)
Figure 5 depicts a graphic representation of the NTA.
RS is a quantitative technique that provides the chemical structure of exosomes based on the 
illumination of analyzed samples by laser light [129]. It is used to study rotational, vibra-
tional, and other low-frequency transitions in a system [130]. Thus, it provides molecular 
fingerprints of the samples and enables monitoring of changes that occur in the molecular 
bond structures [117]. In this method, photons interact with other photons, molecular vibra-
tions, and other excitations in the system. This interaction leads to a slight up or down shift of 
their energy. The shift in energy provides information about the vibrational transitions in the 
molecules [121, 130, 131]. Because of these measurements, the chemical composition of single 
EVs can be obtained [117, 131, 132].
WB is often used to show and confirm the presence of exosomal proteins and specific surface 
markers [133–135]. Specific surface markers include MHC I and MHC II, tetraspanins CD9, 
CD63, CD81, Hsp70 and Hsp90, etc. After EVs are isolated, they are lysed. Following lysis, the 
proteins are separated and analyzed [133]. Although WB is used to identify and confirm the 
presence of exosomal proteins, it cannot determine the presence of EVs alone. However, WB 
can be used to identify proteins in purified exosomal samples [120, 133].
Also, to help investigators validate and/or characterize their findings related to exosomes, 
researchers can use ExoCarta (http://www.exocarta.org/) [136]. ExoCarta is an online data-
base that allows principal investigators the ability to identify and characterize exosomal car-
gos. The database contains detailed information about lipids, proteins, and RNA sequences 
that have been identified in specific exosomal preparations [77].
There are many other methods/techniques that are used to detect, identify, visualize, and 
characterize EVs. Additional techniques that have been used include: Sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS PAGE) [137], Bradford assay [133], Enzyme-
linked immunosorbent assay (ELISA) [133], dynamic light scattering (DLS) [117], mass 
spectrometry [137, 138], atomic force microscopy (AFM) [139], field-flow fractionation 
[140], and resistive pulse sensing [141]. Briefly, SDS PAGE, the Bradford assay, and ELISA 
are used to validate the presence of proteins. In this context, these assays could be used 
to confirm proteins on exosomes and/or proteins located within exosomes. Whereas, mass 
spectrometry, AFM, field-flow fractionation, and sensitive pulse sensing is to observe the 
molecular and physiochemical properties of EVs. These assays are often used to examine, 
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identify, and determine particle size and particle size distribution. Whenever applicable, 
statistical analyses should be performed to check results found from all methodologies. 
These analyses could include but are not limited to, Student T-test and analysis of variance 
(ANOVA).
6. Exosomes in cancer
Exosomes released from cancer cells may impact the cancer microenvironment significantly 
and alter the fate of proximal cells. These exosomes can mediate intracellular communica-
tion between other cancer cells, neighboring stromal cells, and immune cells [142–144]. In 
2014, Boelens and team revealed that exosomes can be transferred from stromal cells to breast 
cancer cells [144, 145]. Due to this transfer, the antiviral retinoic acid-inducible gene 1 enzyme 
signaling can be activated to regulate the development of therapy-resistance tumor-initiating 
cells [144, 145]. Several studies have reported that cancer-derived exosomes play a major 
role in drug resistance, metastasis, angiogenesis, tumorigenesis, tumor growth, and tumor 
immune escape, as depicted in Figure 6 [144, 146, 147].
Figure 5. Representation of exosomes by NanoSight tracking analysis (NTA). Microglia-derived exosomes were 
generated as described in Figure 3 and confirmed by NTA. In brief, we used the NanoSight LM10 (Malvern Instruments, 
Inc., Malvern, UK) and NTA v2.0 software to characterize mouse microglia-derived exosomes. All data were collected 
using five frames and in triplicate. Samples were diluted 1:1000 prior to tracking.
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6.1. Drug resistance
Resistances to chemotherapy, radiation, or targeted therapies are significant challenges in 
the treatment of various cancers [148–150]. Recently, it has been demonstrated that exosomes 
aid in resistance through the transfer of lipids, proteins, mRNAs, and miRNAs [80, 151], 
which can influence the response to anticancer drugs [152]. Corcoran et al. [153] evaluated the 
enhancement of exosome secretion by Docetaxel-resistance in prostate cancer. They observed 
that this enhancement of exosome secretion is due to docetaxel efflux through exosomes [153]. 
Akao et al. [154] observed that the secretion of tumor-suppressors miRs-145 and miR-34 via 
exosomes increased 5-fluorouracil resistance in colon cancer cells.
6.2. Metastasis, angiogenesis, and tumorigenesis
It is believed that exosomes mediate signaling in cancer metastasis [155–158]. Exosomes can 
function as escape routes for miRNAs and proteins that serve as promoters of metastatic 
pathways. The uptake of exosomes by endothelial cells can stimulate angiogenesis [144, 159, 
160]. Grange et al. [159] investigated the role of angiogenesis in renal cell-derived exosomes 
in lung cancer ascites. Exosomes that are stimulated by hypoxia and heparanase- an enzyme 
that acts at the cell surface and within the extracellular matrix to degrade heparan sulfate 
molecules, are associated with angiogenesis of breast cancer, which is the most significant 
Figure 6. Roles of exosomes in cancer. The multifaceted role of exosomes in carcinogenesis.
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part of breast cancer tumorigenesis [145, 149]. Tumorigenesis is the process that occurs when 
normal healthy cells transform into cancerous cells. During this process, these cells can secrete 
exosomes [146, 147]. Several studies have reported that neoplastic transformation of adipose-
derived stem cells was induced in response to prostate cancer-derived exosomes [146, 161]. 
Also, studies have reported that these exosomes deliver mRNA molecules and oncogenic 
proteins to recipient cells; which subsequently induced tumor formation [146, 162].
6.3. Tumor growth and tumor immune escape
Tumor cells secrete many exosomes [163–166]. Supporting evidence has shown that exo-
somes released from tumors promote the formation of tumor blood vessels that support 
tumor growth and extension [144, 146, 149]. Glioblastoma multiforme cell-derived exosomes 
have been proposed to promote tumor growth by transporting RNA into recipient cells in 
the microenvironment [142, 143]. In 2011, Kogure and colleagues showed that hepatocel-
lular carcinoma-derived exosomes can modify the transforming growth factor-β-activated 
kinase 1 expression and associated signaling pathways to augment cell growth in recipient 
cells [144, 167].
Cancer cells utilize exosomes that contain proteins and nucleic acids to enact an immune 
escape [144]. It has been shown that they activate dendritic cells, thus priming the immune 
system to identify and kill cancer cells [168]. Remarkably, exosomes secreted by cancer cells 
have been proven to express tumor antigens, as well as immune suppressive molecules, such 
as Fas ligand and Programmed death-ligand 1 [169]. Taken together, these data suggest that 
cancer cells use exosomes to further advancement of its tumorigenesis.
7. Exosomes in genetic-related diseases
Many types of cells (i.e. neurons, astrocytes, oligodendrocytes, glial) in the central nervous 
system secret exosomes [32, 170–172]. Exosomes have been reported to aid in the spread of 
pathological proteins that are involved in neurodegenerative diseases, such as Alzheimer 
disease (AD) [170, 173], Parkinson’s disease (PD) [171, 173, 174] prion diseases [32, 173] and 
Huntington’s disease (HD) [32]. Current studies have shown that exosomes can spread patho-
logical misfolded proteins, which leads to the onset and propagation of AD [170, 173]. AD is 
the most common form of dementia and characterized by amyloid plaques and neurofibrillary 
tangles [170, 173]. Accumulating evidence has demonstrated that exosomes play a controver-
sial role in the pathogenesis of Alzheimer [170, 173, 175]. Yuyama et al. [176] observed the 
presence of exosome-associated amyloid-ß peptide in the cerebrospinal fluid of cynomolgus 
monkeys and amyloid precursor protein transgenic mice. They concluded that these findings 
could potentially contribute to AD pathogenesis [176].
Many studies have revealed that exosomes derived from the central nervous system occur 
in the cerebrospinal fluid and peripheral body fluids, and their contents are altered during 
disease, making them an appealing target for biomarker development in PD [171, 174]. PD is 
a disorder that occurs due to the loss of dopamine produced in the brain affecting movement 
of the body [172, 177]. Exosomes may aid in the spread of toxic α-synuclein protein between 
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cells and induce apoptosis, which could potentially be proposed as a key mechanism underly-
ing the spread of α-synuclein aggregates in the brain and the acceleration of pathology in PD 
[171, 178]. Comparative studies have shown that the expression of the PD-associated protein 
α-synuclein is targeted by miR-7 and miR-153 [179–181].
Prion diseases also known as transmissible spongiform encephalopathies are a group of 
infectious neurodegenerative disorders that affects animals and humans [172, 182]. These 
diseases are caused by abnormally shaped proteins called prions [177]. Exosome-mediated 
propagation in prion diseases was reported in 2004 by Fevrier et al. [183, 184]. They observed 
that the prion protein (PrP)-expressing cells could release normal PrPC and abnormal PrPSc in 
association with exosomes [183, 184]. The first reported in vivo study related to prion disease 
pathogenesis was demonstrated 4 years later by Vella et al. 2008 [183, 185]. They revealed 
PrPC was associated with extracellular vesicles that were found in the CSF of sheep [183, 185].
HD is a hereditary neurodegenerative disorder that causes progressive degeneration of nerve 
cells in the brain due the aggregation of the mutant Huntingtin protein [186–188]. Lee et al. 
[186] investigated the therapeutic role of exosomes from adipose-derived stem cells by exam-
ining pathological phenotypes of a HD model in vitro. They confirmed that adipose stem 
cell-derived exosomes up-regulates the peroxisome proliferator-activated receptor gamma 
coactivator 1, phosphorylated cyclic AMP response element binding protein, and ameliorates 
abnormal apoptotic protein level in an in vitro HD model [186]. A year later, Soon-Tae Lee 
and colleagues developed an therapeutic exosome-based delivery method to treat HD using 
miR-124, one of the key miRNAs that is repressed in HD [189].
8. Exosomes in infectious diseases
8.1. Viruses
Exosomes derived from virus-infected cells have been shown to carry viral proteins, genetic 
regulatory elements, genomic RNA, mRNA, and miRNA [50, 190, 191]. Depending on the 
genetic material and proteins incorporated into them, EVs may play a vital role in viral infec-
tion, especially in retroviruses [192]. Retroviruses are enveloped RNA viruses that replicate 
through a DNA intermediate inserted in the host cell genome [193]. According to the Trojan 
hypothesis, it is believed that retroviruses exploit preexisting pathways for intracellular 
trafficking [192, 194]. Thus, the Trojan hypothesis states that retroviruses use the preexist-
ing, nonviral exosome biogenesis pathway for the formation of infectious particles, and the 
preexisting, nonviral pathway of exosome uptake for a receptor-independent, enveloped-
independent mode of infection [81, 194–196].
Among the retroviruses, HIV-1 is the most common studied virus [127, 197]. Exosomes iso-
lated from patients with HIV infection or from HIV-1 infected cells incorporate the viral trans-
activating response element that is transcribed from the integrated provirus [50, 198]. This is 
believed to stimulate HIV-1 replication in recipient cells by downregulation of apoptosis [50, 
197–199]. Madison et al. [200] showed that semen-derived exosomes inhibit HIV-1 replication 
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in various cell types. Years later, Madison and colleagues described detailed protocols for 
evaluating the function and physical properties of these semen-derived exosomes [200] for in 
vitro uptake and HIV-1 infection assays [201]. Recently, Sims et al. [92] have demonstrated the 
role of T cell immunoglobulin and mucin proteins (TIM) in exosome-dependent HIV-1 traf-
ficking into human immune cells. Through viral infection assays, they demonstrated that exo-
somes derived from human lung carcinoma, human breast milk, human plasma, and mouse 
neural stem cells, increased HIV-1 entry into macrophages and T cells [92]. Furthermore, they 
demonstrated that HIV-1 and exosome interactions were potentially mediated through bind-
ing of TIM4 to the viral envelope [92]. In another study, Sims and colleagues demonstrated 
that exosomes can enhance HIV-1 entry into human monocytic and T cell lines through exo-
somal tetraspanin proteins CD9 and CD81 [127].
8.2. Bacteria-derived exosomes
Bacteria make and release membranous vesicles [202–204]. Gram-negative bacteria produce 
outer-membrane vesicles that originate from the blebbing of the outer membrane [202]. Also, 
they form vesicles that contain membrane components, nucleic acids, and proteins [202]. 
Many gram-negative bacteria that produce these vesicles are pathogenic and toxic to host 
cells [202, 205–207]. However, they can deliver antigens; and therefore, act as a potential vac-
cine candidate [202, 206, 207].
Gram-positive bacteria produce outer-membrane vesicles [202, 208]. Unlike gram-negative 
bacteria, these vesicles play a role in inter-species and intra-species communications [202, 
209], in addition to potential inter-kingdom interaction with the host [202, 206, 210]. Most 
importantly, these vesicles provide an innovative approach for development of non-live vac-
cines [202]. These vaccines have been successfully used with children infected with Neisseria 
meningitidis in New Zealand [211].
8.3. Parasitic-derived exosomes
There is accumulating evidence that has reported the release of EVs in parasitic diseases, act-
ing in parasite–parasite inter-communication and in parasite-host interactions [212–214]. EVs 
participate in the dissemination of the pathogen and play a vital role in host-pathogen interac-
tions [212, 215]. Vesicles that are secreted by infected cells contain large amounts of pathogen 
molecules, which are sufficient to induce modifications in non-infected neighboring cells or 
act as antigen presenters for the immune system [215]. In 2013, Hassani and Olivier identified 
GP63 surface protease of Leishmania mexicana on exosomes [202, 216]. They observed that this 
protease could be transmitted to distant sites by enzymatic activity [202, 216].
9. Exosomes as diagnostic and therapeutic biomarkers
Exosomes have attracted enormous research interest because of their promising medical 
applications [217–219]. Exosomes may serve as diagnostic tools because they are carriers 
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of molecular markers of many diseases and as a prospective delivery system for various 
therapeutic agents [75, 220–222]. Supporting evidence suggests that exosomes are present 
in all bodily fluids and may be associated with disease pathogenesis [223–226] and may be 
involved in cellular protection [227, 228]. Mostly importantly, they contain various nucleic 
acids, lipids, and proteins. Due to the cargo of exosomes, exosomes are involved in several 
infectious diseases [75]. Because of their endocytic origin, exosomes carry specialized protein 
markers, such as hsps, tetraspanin, and Rab family proteins. Exosomal content is a fingerprint 
of the state (cancer versus quiescent) of the cell and the original cell type.
Exosomes can be used to diagnosis various diseases, such as cancer, AD, PD, HD, etc. [150, 
173, 174, 186, 229]. Non-invasive diagnostics (using saliva and urine samples) or minimum 
invasive diagnostics (based on blood analysis) make exosomes very attractive alternatives 
to excision biopsies or traditional needle biopsies. There are advantages such as lower cost 
analysis, convenience and reduction in patient pain [229].
Exosomes can be exploited as potential carriers for therapeutics [230]. Many anti-inflamma-
tory drugs (i.e. Doxorubicin) can be inserted into purified exosomes for in vivo and in vitro 
applications [231–235]. Sun et al. [236] investigated the anti-inflammatory activities of cur-
cumin when encapsulated in exosomes. A year later, Zhuang and colleagues demonstrated 
that exosomes can be utilized to deliver anti-inflammatory drugs to the brain through a non-
invasive intranasal route [232].
10. Summary
Secreted exosomes have important functions in the pathogenesis of various diseases. Several 
methods have been developed to isolate, purify, and characterize exosomes from biological 
fluids. However, isolation of exosomes can be problematic during the purification process 
due contaminants, such as protein aggregates, microvesicles, microbes, etc. Because of theses 
contaminates, it is challenging to characterize exosomes accurately, and use them for experi-
mental assays. Centrifugation techniques remain very common. However, other methods, 
such as filtration, sucrose density gradient centrifugation, SEC, microfluidics, and ExoQuick™ 
show promising results and can be effectively applied both in laboratory research and clinical 
medicine. It is most important to note that subsequent to exosome purification it is necessary 
to employ a combination of methods to confirm and characterize extracellular vesicles. The 
utilization of multimodality validations will allow researchers to obtain data that is quali-
tative, quantitative or both. Characterization of exosomes allows researchers to understand 
exosomal properties and function. Most importantly, characterization studies allow research-
ers to identify unique exosomal marker proteins to detect the presence of exosomes found in 
cell culture supernatants and biological fluids. The study of EV composition has shown that 
they can carry numerous cargos (i.e. lipids, proteins, and nucleic acids). These cargos can 
vary widely between cells and conditions. Their composition is cell type-dependent that can 
be altered by different environmental factors. The use of exosomes as therapeutic delivery 
vehicles covers a wide array of diseases, including but not limited to cancer, virus-induced 
diseases, genetically related diseases and parasitic diseases.
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